Inactive Instrument

Orgenesis Inc Stock Other OTC

Equities

US68619K1051

Medical Equipment, Supplies & Distribution

Sales 2022 36.02M Sales 2023 530K Capitalization 15.96M
Net income 2022 -14M Net income 2023 -55M EV / Sales 2022 1.8 x
Net Debt 2022 14.96M Net Debt 2023 21.78M EV / Sales 2023 71.2 x
P/E ratio 2022
-3.29 x
P/E ratio 2023
-0.26 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.99%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 70 08-06-04
Chief Executive Officer 55 12-02-01
Director of Finance/CFO 54 Jan. 01
Members of the board TitleAgeSince
Director/Board Member 64 13-07-17
Chief Executive Officer 55 12-02-01
Director/Board Member 54 20-01-08
More insiders
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
More about the company